Biovail to merge with Valeant
This article was originally published in Scrip
Executive Summary
The Canadian firm Biovail is to merge with Valeant Pharmaceuticals of the US in a $3.2 billion deal. The combined company is to be called Valeant Pharmaceuticals International.